STRIBILD

This brand name is authorized in Austria, Canada, Cyprus, Estonia, Spain, Finland, France, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug STRIBILD contains a combination of these active pharmaceutical ingredients (APIs):

1 Elvitegravir
UNII 4GDQ854U53 - ELVITEGRAVIR

Elvitegravir, is a type of antiviral agent called an ‘integrase inhibitor’. It blocks an enzyme called integrase, which is involved in a step in the reproduction of HIV. When the enzyme is blocked, the virus cannot reproduce normally, slowing down the spread of infection.

Read about Elvitegravir
2 Cobicistat
UNII LW2E03M5PG - COBICISTAT

Cobicistat is a mechanism-based inhibitor of cytochromes P450 of the CYP3A subfamily. Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as darunavir, where bioavailability is limited and half-life is shortened due to CYP3A-dependent metabolism.

Read about Cobicistat
3 Emtricitabine
UNII G70B4ETF4S - EMTRICITABINE

Emtricitabine is a synthetic nucleoside analogue of cytidine with activity that is specific to HIV-1, HIV-2 and HBV. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which competitively inhibits HIV-1 reverse transcriptase, resulting in DNA chain termination. Emtricitabine is a weak inhibitor of mammalian DNA polymerase α, β and ε and mitochondrial DNA polymerase γ.

Read about Emtricitabine
4 Tenofovir disoproxil
UNII OTT9J7900I - TENOFOVIR DISOPROXIL FUMARATE

Tenofovir disoproxil is absorbed and converted to the active substance tenofovir, which is a nucleoside monophosphate analogue. Tenofovir is then converted to the active metabolite, tenofovir diphosphate, an obligate chain terminator, by constitutively expressed cellular enzymes. Tenofovir diphosphate inhibits HIV-1 reverse transcriptase and the HBV polymerase by direct binding competition with the natural deoxyribonucleotide substrate and, after incorporation into DNA, by DNA chain termination.

Read about Tenofovir disoproxil

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J05AR09 J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02397137
Country: EE Ravimiamet Identifier(s): 1616149, 1616150
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 113830001
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 168038
Country: FR Base de données publique des médicaments Identifier(s): 65768058
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 231638
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 7426
Country: IT Agenzia del Farmaco Identifier(s): 042815011, 042815023
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1070337, 1070338
Country: NL Z-Index G-Standaard, PRK Identifier(s): 146587
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100156785
Country: SG Health Sciences Authority Identifier(s): 14835P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8698760090083, 8698760090090
Country: US FDA, National Drug Code Identifier(s): 61958-1201

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.